Bernard A, Lauwerys R, Gengoux P
Toxicology. 1981;20(4):345-57. doi: 10.1016/0300-483x(81)90041-x.
Female Sprague-Dawley rats were given 200 ppm cadmium (Cd) in the drinking water for 11 months. Total proteinuria and the concentrations of Cd in blood, urine, liver and kidney cortex were determined monthly. The proteinuria was characterized by Sephadex G-75 chromatography and by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. From the 8th month of treatment, the Cd concentration in the kidney cortex levels off at a value of about 250 microgram/g wet wt and this phenomenon coincides with the occurrence of proteinuria. The proteinuria was characterized by an increased urinary excretion of high molecular weight (HMW) proteins, particularly gamma-globulins. Aminoaciduria also increased which suggests the existence of a slight tubular dysfunction. The renal dysfunction induced by chronic oral administration of Cd seems different from that observed in a previous study in which Cd was administered by the i.p. route (1 mg Cd/kg, 5 times a week for 2 months). For the same level of Cd in the kidney cortex the proteinuria induced by i.p. injection of Cd was usually of mixed type and in some cases of the tubular type. The development of this proteinuria was coincident with the levelling off of Cd concentration in the kidney cortex and in the liver. The saturation of liver by Cd is very likely at the origin of he extensive tubular lesion and of the mixed type proteinuria observed in the i.p. experiment. These results demonstrate the importance of mode of Cd administration on the nature of the Cd-induced proteinuria in animal. They support also our proposal that both low and HMW proteins should be determined in urine for the early detection of renal damage occurring in man chronically exposed to cadmium.
给雌性斯普拉格 - 道利大鼠饮用含200 ppm镉(Cd)的水,持续11个月。每月测定总蛋白尿以及血液、尿液、肝脏和肾皮质中镉的浓度。通过葡聚糖G - 75色谱法和十二烷基硫酸钠 - 聚丙烯酰胺凝胶电泳对蛋白尿进行表征。从治疗的第8个月起,肾皮质中的镉浓度稳定在约250微克/克湿重的水平,这种现象与蛋白尿的出现相吻合。蛋白尿的特征是高分子量(HMW)蛋白质,特别是γ - 球蛋白的尿排泄增加。氨基酸尿也增加,这表明存在轻微的肾小管功能障碍。慢性口服镉诱导的肾功能障碍似乎与先前一项研究中通过腹腔注射途径(1毫克镉/千克,每周5次,持续2个月)给药镉所观察到的不同。对于肾皮质中相同水平的镉,腹腔注射镉诱导的蛋白尿通常为混合型,在某些情况下为肾小管型。这种蛋白尿的发展与肾皮质和肝脏中镉浓度的稳定相吻合。在腹腔注射实验中观察到的广泛肾小管病变和混合型蛋白尿很可能源于肝脏被镉饱和。这些结果证明了镉的给药方式对动物中镉诱导的蛋白尿性质的重要性。它们也支持了我们的提议,即对于长期接触镉的人类中发生的肾损伤的早期检测,应测定尿液中的低分子量和高分子量蛋白质。